Ranbaxy Receives Tentative Approval To Market Risperidone Oral Solution
Mon, 07 Aug 2006 06:00 AM EST
... Ranbaxy Pharmaceuticals Inc.(RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative approval from the U.S. Foodand Drug Administration to manufacture and market Risperidone OralSolution, 1 mg/mL. Risperidone Oral Solution is indicated for the treatment ofschizophrenia. [click link for full article] ...
Related Topics
- Risperidone Oral Solution
- Ergocalciferol, Vitamin D2 Oral Solution
- Stavudine Oral Solution
- Research
- Rofecoxib Oral Suspension
- Cyclosporine Oral Solution
- Risperidone
- Gabapentin Oral Solution
- Alendronate Oral Solution
- Escitalopram Oral Solution
- Acetaminophen and Oxycodone Oral Solution
- Lopinavir and Ritonavir Oral Solution
- Doxepin Oral Solution
- Ritonavir Oral Solution
- Nortriptyline Oral Solution
- Amprenavir Oral Solution
- Galantamine Oral Solution
- Trimethoprim Oral Solution
- Furosemide Oral Solution
- Ribavirin Oral Solution

Not Signed In -

